Möhring J, Möhring B, Petri M, Haack D
Am J Physiol. 1977 Mar;232(3):F260-9. doi: 10.1152/ajprenal.1977.232.3.F260.
During the onset of malignant hypertension (MH) in rats treated with deoxycorticosterone trimethylacetate (DOC), plasma arginine vasopressin (AVP) concentrations increase tenfold as a consequence of hypovolemia and hyperosmolality. In benign hypertensive (BH) rats, plasma AVP is increased threefold in comparison with control animals. Plasma renin is markedly suppressed in both BH and MH animals. In MH rats, biologically active AVP antiserum lowers blood pressure (BP) transiently to normal or subnormal levels; in BH rats, a small BP-lowering effect of the AVP antiserum is seen. (Biologically active angiotensin II antiserum does not lower BP in MH rats.) The relationship between the height of BP and plasma AVP concentration in DOC hypertensive rats indicates, when compared with that relationship in diabetes insipidus rats infused with AVP, a marked enhancement of the vasopressor effect of AVP. These findings and the earlier observation of vasopressin-induced vascular damage by Byrom (F. B. Byrom, The Hypertensive Vascular Crisis. London: Heinemann, 1969) strongly suggest that ADH is involved as a vasopressor hormone in the pathogenesis of malignant DOC hypertension.
在用三甲基乙酸脱氧皮质酮(DOC)治疗的大鼠发生恶性高血压(MH)期间,由于血容量减少和高渗状态,血浆精氨酸加压素(AVP)浓度增加了10倍。在良性高血压(BH)大鼠中,与对照动物相比,血浆AVP增加了3倍。BH和MH动物的血浆肾素均明显受到抑制。在MH大鼠中,生物活性AVP抗血清可使血压(BP)短暂降至正常或低于正常水平;在BH大鼠中,可见AVP抗血清有轻微的降压作用。(生物活性血管紧张素II抗血清对MH大鼠的血压无降低作用。)与注入AVP的尿崩症大鼠的血压与血浆AVP浓度之间的关系相比,DOC高血压大鼠的这种关系表明AVP的升压作用明显增强。这些发现以及Byrom(F. B. Byrom,《高血压血管危机》。伦敦:Heinemann,1969年)早期关于加压素诱导血管损伤的观察结果强烈提示,抗利尿激素作为一种升压激素参与了恶性DOC高血压的发病机制。